Point72 Asset Management, L.P. 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 7:50 pm Sale |
2024-09-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Point72 Asset Management, L.P. | 247,055 0.200% |
-4,620,651 (-94.92%) |
Filing |
| 2024-01-31 4:54 pm Purchase |
2024-01-30 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Point72 Asset Management, L.P. | 4,867,706 5.200% |
3,680,108 (+309.88%) |
Filing |
| 2023-02-14 4:04 pm Sale |
2022-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Point72 Asset Management, L.P. | 1,187,598 1.900% |
-1,470,364 (-55.32%) |
Filing |
| 2022-02-14 4:27 pm Purchase |
2021-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Point72 Asset Management, L.P. | 2,657,962 5.300% |
107,226 (+4.20%) |
Filing |
| 2021-12-15 5:14 pm Purchase |
2021-12-14 | 13G | Arcutis Biotherapeutics, Inc. ARQT |
Point72 Asset Management, L.P. | 2,550,736 5.100% |
2,550,736 (New Position) |
Filing |